Skip to main content
SpringerLink
Log in

Systemic Lupus Erythematosus: Indirect B-Cell Blocking

  • Chapter
  • First Online:
Drugs Targeting B-Cells in Autoimmune Diseases

Part of the book series: Milestones in Drug Therapy ((MDT))

  • 1225 Accesses

Abstract

The use of B-cell depleting agents in clinical practice in systemic lupus erythematosus (SLE), overwhelmingly restricted to off-label therapy with rituximab, currently centers on patients unresponsive or intolerant to standard of care therapy, or with life-threatening presentations. Four B-cell depleting agents deserve specific mention: rituximab, use of which is reported in nearly 1,500 patients with SLE (1,000 in uncontrolled studies); ocrelizumab, trials of which were halted in 2010 owing to an association with unexpectedly high rates of severe infections; epratuzumab, which has been tested in trials that enrolled nearly 300 patients with SLE; and belimumab, tested in more than 2,000 patients with SLE overwhelmingly included in controlled trials. Belimumab has been licensed for use in SLE in 2011 by the FDA and European Medicines Agency. Forthcoming years will show the real value of B-cell targeted therapies, including the off-label use of rituximab and especially the licensed use of belimumab, as part of the standard of care in patients with SLE.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 129.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Hardcover Book
USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  • Bernatsky S, Ramsey-Goldman R, Labrecque J, Joseph L, Boivin JF, Petri M, Zoma A, Manzi S, Urowitz MB, Gladman D, Fortin PR, Ginzler E, Yelin E, Bae SC, Wallace DJ, Edworthy S, Jacobsen S, Gordon C, Dooley MA, Peschken CA, Hanly JG, Alarcón GS, Nived O, Ruiz-Irastorza G, Isenberg D, Rahman A, Witte T, Aranow C, Kamen DL, Steinsson K, Askanase A, Barr S, Criswell LA, Sturfelt G, Patel NM, Senécal JL, Zummer M, Pope JE, Ensworth S, El-Gabalawy H, McCarthy T, Dreyer L, Sibley J, St Pierre Y, Clarke AE (2013a) Cancer risk in systemic lupus: an updated international multi-centre cohort study. J Autoimmun 42:130–135

    Article  PubMed  Google Scholar 

  • Bernatsky S, Ramsey-Goldman R, Joseph L, Boivin JF, Costenbader KH, Urowitz MB, Gladman DD, Fortin PR, Nived O, Petri MA, Jacobsen S, Manzi S, Ginzler EM, Isenberg D, Rahman A, Gordon C, Ruiz-Irastorza G, Yelin E, Bae SC, Wallace DJ, Peschken CA, Dooley MA, Edworthy SM, Aranow C, Kamen DL, Romero-Diaz J, Askanase A, Witte T, Barr SG, Criswell LA, Sturfelt GK, Blanco I, Feldman CH, Dreyer L, Patel NM, St Pierre Y, Clarke AE. (2013b) Lymphoma risk in systemic lupus: effects of disease activity versus treatment. Ann Rheum Dis [Epub ahead of print] PubMed PMID: 23303389

    Google Scholar 

  • Burness CB, McCormack PL (2011) Belimumab: in systemic lupus erythematosus. Drugs 71:2435–2444

    Article  PubMed  CAS  Google Scholar 

  • Cancro MP, D’Cruz DP, Khamashta MA (2009) The role of B lymphocyte stimulator (BLyS) in systemic lupus erythematosus. J Clin Invest 119:1066–1073

    Article  PubMed  CAS  Google Scholar 

  • Chiche L, Jourde N, Mancini J (2011) Belimumab for systemic lupus erythematosus. Lancet 377:2080

    Article  PubMed  Google Scholar 

  • Coca A, Sanz I (2012) Updates on B-cell immunotherapies for systemic lupus erythematosus and Sjogren’s syndrome. Curr Opin Rheumatol 24:451–456

    PubMed  CAS  Google Scholar 

  • D’Cruz D, Manzi S, Sánchez-Guerrero J, BLISS-52 and BLISS-76 Study Groups (2011) Belimumab reduced disease activity across multiple organ domains in patients with SLE: combined results from BLISS-52 and BLISS-76. Ann Rheum Dis (Abstract THU0421)

    Google Scholar 

  • Dall’Era M, Chakravarty E, Wallace D, Genovese M, Weisman M, Kavanaugh A, Kalunian K, Dhar P, Vincent E, Pena-Rossi C, Wofsy D (2007) Reduced B lymphocyte and immunoglobulin levels after atacicept treatment in patients with systemic lupus erythematosus: results of a multicenter, phase Ib, double-blind, placebo-controlled, dose-escalating trial. Arthritis Rheum 56:4142–4150

    Article  PubMed  Google Scholar 

  • Dooley MD, Houssiau F, Aranow C, D’Cruz D, Askanase AD, Roth D, Zhong ZJ, Freimuth W, Ginzler EM, BLISS-52/-76 Study Groups (2011) Effect of belimumab treatment on renal outcomes: results from phase 3 belimumab clinical trials in patients with systemic lupus erythematosus. Arthritis Rheum 63(Suppl):2472(S963)

    Google Scholar 

  • Engel P, Gómez-Puerta JA, Ramos-Casals M, Lozano F, Bosch X (2011) Therapeutic targeting of B cells for rheumatic autoimmune diseases. Pharmacol Rev 63:127–156

    Article  PubMed  CAS  Google Scholar 

  • European Medicines Agency (EMEA) (2013) Benlysta leaflet. http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/002015/human_med_001466.jsp&mid=WC0b01ac058001d124&jsenabled=true. Accessed 15 Apr 2013

  • Furie R, Petri M, Zamani O, Cervera R, Wallace DJ, Tegzová D, Sanchez-Guerrero J, Schwarting A, Merrill JT, Chatham WW, Stohl W, Ginzler EM, Hough DR, Zhong ZJ, Freimuth W, van Vollenhoven RF, BLISS-76 Study Group (2011) A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus. Arthritis Rheum 63:3918–3930

    Article  PubMed  CAS  Google Scholar 

  • Genovese MC, Kinnman N, de La Bourdonnaye G, Pena Rossi C, Tak PP (2011) Atacicept in patients with rheumatoid arthritis and an inadequate response to tumor necrosis factor antagonist therapy: results of a phase II, randomized, placebo-controlled, dose-finding trial. Arthritis Rheum 63:1793–1803

    Article  PubMed  CAS  Google Scholar 

  • Ginzler EM, Wax S, Rajeswaran A, Copt S, Hillson J, Ramos E, Singer NG (2012) Atacicept in combination with MMF and corticosteroids in lupus nephritis: results of a prematurely terminated trial. Arthritis Res Ther 14:R33

    Article  PubMed  CAS  Google Scholar 

  • Gregersen JW, Jayne DR (2012) B-cell depletion in the treatment of lupus nephritis. Nat Rev Nephrol 9:505–514

    Article  Google Scholar 

  • Hahn BH (2013) Belimumab for systemic lupus erythematosus. N Engl J Med 368(16):1528–1535

    Article  PubMed  CAS  Google Scholar 

  • Herbst R, Wang Y, Gallagher S, Mittereder N, Kuta E, Damschroder M, Woods R, Rowe DC, Cheng L, Cook K, Evans K, Sims GP, Pfarr DS, Bowen MA, Dall’Acqua W, Shlomchik M, Tedder TF, Kiener P, Jallal B, Wu H, Coyle AJ (2010) B-cell depletion in vitro and in vivo with an afucosylated anti-CD19 antibody. J Pharmacol Exp Ther 335:213–222, Erratum in: J Pharmacol Exp Ther 2011, 336, 294

    Article  PubMed  CAS  Google Scholar 

  • Horowitz DL, Furie R (2012) Belimumab is approved by the FDA: what more do we need to know to optimize decision making? Curr Rheumatol Rep 14:318–323

    Article  PubMed  CAS  Google Scholar 

  • Jiménez-Alonso J (2012) Clinical guidelines of the Spanish Society of Internal Medicine: Systemic lupus erythematosus, Spanish Study Group of Systemic Autoimmune Diseases (GEAS) http://www.fesemi.org/grupos/autoinmunes/docencia/guias/view#les_2011

  • Li J, Pan HF, Cen H, Tian J, Ma Y, Tao JH, Ye DQ (2011) Interleukin-21 as a potential therapeutic target for systemic lupus erythematosus. Mol Biol Rep 38:4077–4081

    Article  PubMed  CAS  Google Scholar 

  • Lied GA, Berstad A (2011) Functional and clinical aspects of the B-cell-activating factor (BAFF): a narrative review. Scand J Immunol 73:1–7

    Article  PubMed  CAS  Google Scholar 

  • Manzi S, Gladman D, Navarra S, Sanchez-Guerrero J, D’Cruz D, Freimuth W, Zhong ZJ, Keenan G and BLISS-52 and BLISS-76 Study Groups (2011) Organ domain item analysis of systemic lupus erythematosus patients treated in phase 3 belimumab clinical trials. Arthritis Rheum 63(Suppl):602(S231)

    Google Scholar 

  • Manzi S, Sánchez-Guerrero J, Merrill JT, Furie R, Gladman D, Navarra SV, Ginzler EM, D’Cruz DP, Doria A, Cooper S, Zhong ZJ, Hough D, Freimuth W, Petri MA, The BLISS-52 and BLISS-76 Study Groups (2012) Effects of belimumab, a B lymphocyte stimulator-specific inhibitor, on disease activity across multiple organ domains in patients with systemic lupus erythematosus: combined results from two phase III trials. Ann Rheum Dis 71:1833–1838

    Article  PubMed  CAS  Google Scholar 

  • Mariño E, Grey ST (2012) B cells as effectors and regulators of autoimmunity. Autoimmunity 45:377–387

    Article  PubMed  Google Scholar 

  • Mauri C, Bosma A (2012) Immune regulatory function of B cells. Annu Rev Immunol 30:221–241

    Article  PubMed  CAS  Google Scholar 

  • Merrill JT, Neuwelt CM, Wallace DJ, Shanahan JC, Latinis KM, Oates JC, Utset TO, Gordon C, Isenberg DA, Hsieh HJ, Zhang D, Brunetta PG (2010) Efficacy and safety of rituximab in moderately-to-severely active systemic lupus erythematosus: the randomized, double-blind, phase II/III systemic lupus erythematosus evaluation of rituximab trial. Arthritis Rheum 62:222–233

    Article  PubMed  CAS  Google Scholar 

  • Merrill JT, Ginzler EM, Wallace DJ, McKay JD, Lisse JR, Aranow C, Wellborne FR, Burnette M, Condemi J, Zhong ZJ, Pineda L, Klein J, Freimuth WW, LBSL02/99 Study Group (2012) Long-term safety profile of belimumab plus standard therapy in patients with systemic lupus erythematosus. Arthritis Rheum 64:3364–3373

    Article  PubMed  CAS  Google Scholar 

  • Morel J, Hahne M (2013) To target or not to target APRIL in systemic lupus erythematosus: that is the question! Arthritis Res Ther 15:107

    Article  PubMed  CAS  Google Scholar 

  • Navarra SV, Guzmán RM, Gallacher AE, BLISS-52 Study Group et al (2011) Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial. Lancet 377:721–731

    Article  PubMed  CAS  Google Scholar 

  • Pena-Rossi C, Nasonov E, Stanislav M, Yakusevich V, Ershova O, Lomareva N, Saunders H, Hill J, Nestorov I (2009) An exploratory dose-escalating study investigating the safety, tolerability, pharmacokinetics and pharmacodynamics of intravenous atacicept in patients with systemic lupus erythematosus. Lupus 18:547–555

    Article  PubMed  CAS  Google Scholar 

  • Petri M, Hu W, Fang H, Xu J, Bienkowska J, Allaire N, Carulli J, Linnik MD (2011) Association between B-Cell activating factor gene expression and disease characteristics in systemic lupus erythematosus. Arthritis Rheum 63(Suppl):585(S223)

    Google Scholar 

  • Ramos-Casals M, Khamashta MA (2012) Connective tissue disease: trial of SLE therapies in real-world settings. Nat Rev Rheumatol 8:128–130

    Article  PubMed  CAS  Google Scholar 

  • Ramos-Casals M, Díaz-Lagares C, Khamashta MA (2009a) Rituximab and lupus: good in real life, bad in controlled trials. Comment on the article by Lu et al. Arthritis Rheum 61:1281–1282

    Article  PubMed  CAS  Google Scholar 

  • Ramos-Casals M, Soto MJ, Cuadrado MJ, Khamashta MA (2009b) Rituximab in systemic lupus erythematosus: a systematic review of off-label use in 188 cases. Lupus 18:767–776

    Article  PubMed  CAS  Google Scholar 

  • Ramos-Casals M, Díaz-Lagares C, Khamashta MA, Grupo de Trabajo de Enfermedades Autoinmunes Sistémicas de la Sociedad Española de Medicina Interna (2011a) B-cell-depletion therapy in systemic autoimmune diseases. Recommendations for use in clinical practice. Med Clin (Barc) 12:257–263

    Article  Google Scholar 

  • Ramos-Casals M, Diaz-Lagares C, Soto-Cardenas MJ, Brito-Zeron P, Cuadrado MJ, Sanna G, Bertolaccini L, Khamashta MA (2011b) Rituximab therapy in lupus nephritis: current clinical evidence. Clin Rev Allergy Immunol 40:159–169

    Article  PubMed  CAS  Google Scholar 

  • Ramos-Casals M, Sanz I, Bosch X, Stone JH, Khamashta MA (2012) B-cell-depleting therapy in systemic lupus erythematosus. Am J Med 125:327–336

    Article  PubMed  CAS  Google Scholar 

  • Ramos-Casals M, Ruiz-Irastorza G, Jiménez-Alonso J, Khamashta MA, Grupo de Trabajo de Enfermedades Autoinmunes Sistémicas (GEAS) de la Sociedad Española de Medicina Interna (SEMI) (2013) Belimumab in systemic lupus erythematosus: a guide for its use in the daily practice. Rev Clin Esp 213:66–67

    Article  PubMed  CAS  Google Scholar 

  • Rovin BH, Furie R, Latinis K, Looney RJ, Fervenza FC, Sanchez-Guerrero J, Maciuca R, Zhang D, Garg JP, Brunetta P, Appel G, LUNAR Investigator Group (2012) Efficacy and safety of rituximab in patients with active proliferative lupus nephritis: the lupus nephritis assessment with rituximab study. Arthritis Rheum 64:1215–1226

    Article  PubMed  CAS  Google Scholar 

  • Ruiz-Irastorza G, Danza A, Khamashta M (2012) Glucocorticoid use and abuse in SLE. Rheumatology (Oxford) 51:1145–1153

    Article  CAS  Google Scholar 

  • Sanz I, Yasothan U, Kirkpatrick P (2011) Belimumab. Nat Rev Drug Discov 10:335–336

    Article  PubMed  CAS  Google Scholar 

  • Scott LJ, Burness CB, McCormack PL (2012) Belimumab: a guide to its use in systemic lupus erythematosus. BioDrugs 26:195–199

    Article  PubMed  CAS  Google Scholar 

  • Stohl W, Hilbert DM (2012) The discovery and development of belimumab: the anti-BLyS-lupus connection. Nat Biotechnol 30:69–77

    Article  PubMed  CAS  Google Scholar 

  • Strand V, Cooper S, Zhong ZJ, Dennis G (2011) Responders in the phase 3 belimumab clinical trials in patients with systemic lupus erythematosus reported improvements in fatigue and health-related quality of life at week 52. Arthritis Rheum 63 (Suppl):1369(S535)

    Google Scholar 

  • Treamtrakanpon W, Tantivitayakul P, Benjachat T, Somparn P, Kittikowit W, Eiam-Ong S, Leelahavanichkul A, Hirankarn N, Avihingsanon Y (2012) APRIL, a proliferation-inducing ligand, as a potential marker of lupus nephritis. Arthritis Res Ther 14:R252

    Article  PubMed  CAS  Google Scholar 

  • van Vollenhoven RF, Kinnman N, Vincent E, Wax S, Bathon J (2011a) Atacicept in patients with rheumatoid arthritis and inadequate response to methotrexate: results of a phase II, randomized, placebo-controlled trial. Arthritis Rheum 63:1782–1792

    Article  PubMed  Google Scholar 

  • van Vollenhoven RF, Schwarting A, Navarra S, et al (2011b) Durability of response in SLE patients treated with belimumab in the phase 3 BLISS-52 and BLISS-76 studies. Ann Rheum Dis (Abstract THU0431)

    Google Scholar 

  • van Vollenhoven RF, Petri MA, Cervera R, Roth DA, Ji BN, Kleoudis CS, Zhong ZJ, Freimuth W (2012) Belimumab in the treatment of systemic lupus erythematosus: high disease activity predictors of response. Ann Rheum Dis 71:1343–1349

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Sjögren Syndrome Research Group (AGAUR), Laboratory of Autoimmune Diseases Josep Font, IDIBAPS, Department of Autoimmune Diseases, ICMiD, Hospital Clínic, Barcelona, Spain

    Pilar Brito-Zerón, Soledad Retamozo & Manuel Ramos-Casals

  2. Department of Internal Medicine, Puerta del Mar University Hospital, Cádiz, Spain

    Ma José Soto-Cárdenas

  3. Department of Internal Medicine, ICMiD, Hospital Clínic, IDIBAPS, University of Barcelona, Barcelona, Spain

    Xavier Bosch

  4. Lupus Research Unit, The Rayne Institute, St. Thomas’ Hospital, King’s College, London, UK

    Munther A. Khamashta

Authors
  1. Pilar Brito-Zerón
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Ma José Soto-Cárdenas
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Soledad Retamozo
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Xavier Bosch
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Manuel Ramos-Casals
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Munther A. Khamashta
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Munther A. Khamashta .

Editor information

Editors and Affiliations

  1. Hospital Clinic, Department of Internal Medicine, University of Barcelona, Barcelona, Spain

    Xavier Bosch

  2. Department of Autoimmune Diseases, Hospital Clinic, Barcelona, Spain

    Manuel Ramos-Casals

  3. King's College, The Rayne Institute, St. Thomas' Hospital, London, United Kingdom

    Munther A Khamashta

Rights and permissions

Reprints and permissions

Copyright information

© 2014 Springer Basel

About this chapter

Cite this chapter

Brito-Zerón, P., Soto-Cárdenas, M.J., Retamozo, S., Bosch, X., Ramos-Casals, M., Khamashta, M.A. (2014). Systemic Lupus Erythematosus: Indirect B-Cell Blocking. In: Bosch, X., Ramos-Casals, M., Khamashta, M. (eds) Drugs Targeting B-Cells in Autoimmune Diseases. Milestones in Drug Therapy. Springer, Basel. https://doi.org/10.1007/978-3-0348-0706-7_5

Download citation

Publish with us

Policies and ethics

Search

Navigation